Cargando…

Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)

BACKGROUND: Public drug plans are faced with increasingly difficult funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) makes funding recommendations to the provincial and territorial drug plans responsible for cancer drugs. Assessments of the economic models submitted by pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Masucci, Lisa, Beca, Jaclyn, Sabharwal, Mona, Hoch, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711746/
https://www.ncbi.nlm.nih.gov/pubmed/29441502
http://dx.doi.org/10.1007/s41669-017-0018-3
_version_ 1783283078484983808
author Masucci, Lisa
Beca, Jaclyn
Sabharwal, Mona
Hoch, Jeffrey S.
author_facet Masucci, Lisa
Beca, Jaclyn
Sabharwal, Mona
Hoch, Jeffrey S.
author_sort Masucci, Lisa
collection PubMed
description BACKGROUND: Public drug plans are faced with increasingly difficult funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) makes funding recommendations to the provincial and territorial drug plans responsible for cancer drugs. Assessments of the economic models submitted by pharmaceutical manufacturers are publicly reported. OBJECTIVES: The main objective of this research was to identify recurring methodological issues in economic models submitted to pCODR for funding reviews. The secondary objective was to explore whether there exists any observed relationships between reported methodological issues and funding recommendations made by pCODR’s expert review committee. METHODS: Publicly available Economic Guidance Reports from July 2011 (inception) until June 2014 for drug reviews with a final funding recommendation (N = 34) were independently examined by two authors. Major methodological issues from each review were abstracted and grouped into nine main categories. Each issue was also categorized based on perception of the reviewer’s actions to manage it. RESULTS: The most commonly reported issues involved costing (59% of reviews), time horizon (56%), and model structure (36%). Several types of issues were identified that usually could not be resolved, such as quality of clinical data or uncertainty with indirect comparisons. Issues with costing or choice of utility estimates could usually be addressed or explored by reviewers. No statistically significant relationship was found between any methodological issue and funding recommendations from the expert review committee. CONCLUSIONS: The findings provide insights that can be used by parties who submit or review economic evidence for continuous improvement and consistency in economic modeling, reporting, and decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s41669-017-0018-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5711746
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-57117462017-12-18 Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) Masucci, Lisa Beca, Jaclyn Sabharwal, Mona Hoch, Jeffrey S. Pharmacoecon Open Original Research Article BACKGROUND: Public drug plans are faced with increasingly difficult funding decisions. In Canada, the pan-Canadian Oncology Drug Review (pCODR) makes funding recommendations to the provincial and territorial drug plans responsible for cancer drugs. Assessments of the economic models submitted by pharmaceutical manufacturers are publicly reported. OBJECTIVES: The main objective of this research was to identify recurring methodological issues in economic models submitted to pCODR for funding reviews. The secondary objective was to explore whether there exists any observed relationships between reported methodological issues and funding recommendations made by pCODR’s expert review committee. METHODS: Publicly available Economic Guidance Reports from July 2011 (inception) until June 2014 for drug reviews with a final funding recommendation (N = 34) were independently examined by two authors. Major methodological issues from each review were abstracted and grouped into nine main categories. Each issue was also categorized based on perception of the reviewer’s actions to manage it. RESULTS: The most commonly reported issues involved costing (59% of reviews), time horizon (56%), and model structure (36%). Several types of issues were identified that usually could not be resolved, such as quality of clinical data or uncertainty with indirect comparisons. Issues with costing or choice of utility estimates could usually be addressed or explored by reviewers. No statistically significant relationship was found between any methodological issue and funding recommendations from the expert review committee. CONCLUSIONS: The findings provide insights that can be used by parties who submit or review economic evidence for continuous improvement and consistency in economic modeling, reporting, and decision making. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s41669-017-0018-3) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-03-22 /pmc/articles/PMC5711746/ /pubmed/29441502 http://dx.doi.org/10.1007/s41669-017-0018-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Masucci, Lisa
Beca, Jaclyn
Sabharwal, Mona
Hoch, Jeffrey S.
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title_full Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title_fullStr Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title_full_unstemmed Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title_short Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)
title_sort methodological issues in economic evaluations submitted to the pan-canadian oncology drug review (pcodr)
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711746/
https://www.ncbi.nlm.nih.gov/pubmed/29441502
http://dx.doi.org/10.1007/s41669-017-0018-3
work_keys_str_mv AT masuccilisa methodologicalissuesineconomicevaluationssubmittedtothepancanadianoncologydrugreviewpcodr
AT becajaclyn methodologicalissuesineconomicevaluationssubmittedtothepancanadianoncologydrugreviewpcodr
AT sabharwalmona methodologicalissuesineconomicevaluationssubmittedtothepancanadianoncologydrugreviewpcodr
AT hochjeffreys methodologicalissuesineconomicevaluationssubmittedtothepancanadianoncologydrugreviewpcodr